

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/750,118		12/31/2003	Peter Sterling Mueller	893-2 CIP II /DIV	9765	
23869 7590 03/02/2006			EXAM	(AMINER		
HOFFMAN		•			IONES, DWAYNE C	
6900 JERICHO TURNPIKE SYOSSET, NY 11791				ART UNIT PAPER NUMBI		
STOSSET,	111/3	71		1614		

DATE MAILED: 03/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

			Application No.	Applicant(s)							
Office Action Summary			10/750,118	MUELLER, PETER STERLING							
			Examiner	Art Unit							
			Dwayne C. Jones	1614							
Pe		The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence ad	ldress						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).											
St	atus										
	1)[]	Responsive to communication(s) filed on									
•	'=	•	-· action is non-final.								
		.—	s application is in condition for allowance except for formal matters, prosecution as to the merits is								
	٠,١	closed in accordance with the practice under E			· · · · · · · · · · · · · · · · · · ·						
Di	spositi	on of Claims									
	4) Claim(s) 1,3,5-7,10,11,18,19,22,23,26-28 and 31-41 is/are pending in the application.										
	•	4a) Of the above claim(s) is/are withdray									
		5) Claim(s) is/are allowed.									
	•	Claim(s) is/are rejected.									
		Claim(s) is/are rejected.									
		8)⊠ Claim(s) <u>See Continuation Sheet</u> are subject to restriction and/or election requirement.									
Αŗ	plicati	on Papers									
	9)[]	The specification is objected to by the Examine	r								
	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.										
	,	Applicant may not request that any objection to the	•								
				, ,	FR 1 121(d)						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.										
Pr	iority u	inder 35 U.S.C. § 119									
		Acknowledgment is made of a claim for foreign All b) Some * c) None of:		-(d) or (f).							
		1. Certified copies of the priority documents have been received.									
	2. Certified copies of the priority documents have been received in Application No										
		3. Copies of the certified copies of the prior	•	d in this National	Stage						
	application from the International Bureau (PCT Rule 17.2(a)).										
	* S	ee the attached detailed Office action for a list of	of the certified copies not receive	d.							
	achmen	· ·	_								
1) [		e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da								
≤/ L 3) [	_	e of Draftsperson's Patent Drawing Review (P10-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	5) Notice of Informal Pa		D-152)						
, .		r No(s)/Mail Date	6) Other:		-						

Application/Control Number: 10/750,118

Art Unit: 1614

## **DETAILED ACTION**

Page 2

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 1 and 3, drawn to a method of enhancing or stimulating neurogenesis, classified in class 514, subclass 646+.
  - II. Claims 5-7, drawn to a method of treating symptoms of Cerebral Palsy, classified in class 514, subclass 646+.
  - III. Claims 10-11, drawn to a method for the treatment of the symptoms of Torticollis, classified in class 514, subclass 646+.
  - IV. Claims 14-17, drawn to a method for the treatment of the symptoms ofDystonia, classified in class 514, subclass 646+.
  - V. Claims 18-19, drawn to a method for the treatment of the symptoms of
     Dyskinesia, classified in class 514, subclass 646+.
  - VI. Claims 22-23, drawn to a method for the treatment of the symptoms of Institutionalization and Concentration Camp Syndromes, classified in class 514, subclass 646+.
  - VII. Claims 26-28, drawn to a method for the treatment of the symptoms of Dementia, classified in class 514, subclass 646+.
  - VIII. Claims 31-32, drawn to a method for the treatment of neurological, behavioral, and cognitive disorders, classified in class 514, subclass 646+.

Application/Control Number: 10/750,118

Art Unit: 1614

IX. Claim 33, drawn to a method for the treatment of the symptoms of Sick Building Syndrome, classified in class 514, subclass 646+.

Page 3

- Claim 34, drawn to a method for the treatment of the symptoms of Gulf
   War Syndrome, classified in class 514, subclass 646+.
- XI. Claims 35-38, drawn to a method for the treatment of the symptoms of Reflex Sympathetic Dystrophy Syndrome or Complex Regional Pain Syndrome, classified in class 514, subclass 646+.
- XII. Claim 39, drawn to a method for the treatment of the symptoms of Retinitis Pigmentosa, classified in class 514, subclass 646+.
- XIII. Claim 40, drawn to a method for the treatment of the symptoms of organic brain impairments, classified in class 514, subclass 646+.
- XIV. Claim 41, drawn to a method for the treatment of the sexual disorders, classified in class 514, subclass 646+.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I and (II-XIV) are unrelated. Inventions are unrelated if it can be shown that they different effects. In the instant case the different inventions, are each directed to treating a variety of separate and distinct diseases and symptoms of various disease states.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/750,118

Art Unit: 1614

4. Claims 1, 5, 6, 10, 18, 22, 26, and 27 are generic to the following disclosed patentably distinct species: a compound that is a selective inhibitor for dopamine, serotonin, and norepinephrine.

Page 4

- 5. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 6. Claim 18 is generic to a plurality of disclosed patentably distinct species comprising Dyskinesia, Tardive Dyskinesia, Lingual Dyskinesia and Facial Dyskinesia. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.
- 7. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 8. Claims 26 and 27 are generic to a plurality of disclosed patentably distinct species comprising Dementia, Alzheimer's dementia, and non-Alzheimer's dementia.

Art Unit: 1614

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

- 9. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 10. A telephone call to the attorney is not required where: 1) the restriction requirement is complex, 2) the application is being prosecuted pro se, or 3) the examiner knows from past experience that a telephone election will not be made, see MPEP Sect. 812.01.
- 11. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Art Unit: 1614

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-

1235.

PRIMARY EXAMINER

Tech. Otr. 1614

February 28, 2006

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 1,3,5-7,10,11,18,19,22,23,26-28 and 31-41.